Menopausal Hormone Therapy: Current Review and its Acceptability and Challenges in the Indian Context
Main Article Content
Abstract
Menopause brings hormonal shifts with physical and emotional symptoms. This article delves into Menopausal Hormone Therapy (MHT), vital for global symptom management but hindered by sociocultural, economic, and healthcare factors in India. Despite efficacy, skepticism persists, amplified by post-Women's Health Initiative concerns. Economic challenges, cultural beliefs favoring traditional therapies, and limited health literacy impede MHT adoption, especially in rural areas. Healthcare provider attitudes and time constraints further complicate usage. Addressing these barriers demands tailored interventions integrating cultural preferences and improving health literacy. The review also explores physiological changes in menopause and suggests receptor-specific therapies for tailored treatment. Further research is crucial to bridge knowledge gaps and understand healthcare provider perspectives, enhancing MHT acceptance and supporting menopausal women. By tackling these challenges, healthcare providers can empower women with informed decisions, ultimately enhancing their quality of life.
Downloads
Article Details
Section
How to Cite
References
1. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Annals of Internal Med. 2005;142(12):1003. DOI: https://doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00117
2. Menopause. https://www.who.int/news-room/fact-sheets/detail/menopause . Accessed Mar 25, 2025.
3. Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021 Jan 1;106(1):1–15. DOI: https://doi.org/10.1210/clinem/dgaa764
4. Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopause Hormone Therapy. Medicina (Kaunas). 2019 Oct 1;55(10):668. DOI: https://doi.org/10.3390/medicina55100668
5. Durairaj A, Venkateshvaran S. Determinants of Menopausal Symptoms and Attitude Towards Menopause Among Midlife Women: A Cross-Sectional Study in South India. Cureus. 2022 Sep;14(9).e28718. DOI: https://doi.org/10.7759/cureus.28718
6. Górecka K, Krzyżanowska M. Prevalence of menopausal hormone therapy and alternative methods, health benefits experienced by peri- and postmenopausal Polish women. Prz Menopauzalny. 2022 Mar;21(1):27–36. DOI: https://doi.org/10.5114/pm.2022.113731
7. Fait T. Menopause hormone therapy: latest developments and clinical practice. Drugs Context. 2019;8:212551. DOI: https://doi.org/10.7573/dic.212551
8. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med. 2005;118(12):64–73. DOI: https://doi.org/10.1016/j.amjmed.2005.09.059
9. Khadilkar S. Hormone Replacement Therapy: An Update. J Obstet Gynaecol India. 2012;62(3):261–5. DOI: https://doi.org/10.1007/s13224-012-0269-y
10. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. DOI: https://doi.org/10.1001/jama.288.3.321
11. Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW. Updated practical recommendations for hormone replacement therapy in the peri-and postmenopause. Climacteric. 2008;11(2):108-23. DOI: https://doi.org/10.1080/13697130801983921
12. Fait T, Fialova A, Pastor Z. The use of estradiol metered-dose transdermal spray in clinical practice. Climacteric. 2018;21(6):549-53. DOI: https://doi.org/10.1080/13697137.2018.1504916
13. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol–progestogen therapy. Obstet Gynecol. 2009;113(1):65-73. DOI: https://doi.org/10.1097/AOG.0b013e31818e8cd6
14. Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. UpToDate, Crowley Jr. WF. 2017 Jun 5:2-150. https://www.uptodate.com/contents/treatment-of-menopausal-symptoms-with-hormonetherapy . Accessed Mar 25, 2025.
15. Lakshmi RM, Kusumalatha K, Shraddha S. Analysis of 200 perimenopausal women: A Prospective Study. Paper presented at 12(th) National Indian Menopause Society Meeting;, 2007; Rajkot, India.
16. Mehta J, Kling JM, Manson JE. Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. Front Endocrinol (Lausanne). 2021;12:564781. DOI: https://doi.org/10.3389/fendo.2021.564781
17. Baber RJ, Panay N, Fenton AT. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50. DOI: https://doi.org/10.3109/13697137.2015.1129166
18. Palacios S, Stevenson JC, Schaudig K, Lukasiewicz M, Graziottin A. Hormone therapy for first-line management of menopausal symptoms: Practical recommendations. Womens Health (Lond). 2019;15:1745506519864009. DOI: https://doi.org/10.1177/1745506519864009
19. Lobo RA. What the future holds for women after menopause: where we have been, where we are, and where we want to go. Climacteric [Internet]. 2014;17(sup2):12-17. DOI: https://doi.org/10.3109/13697137.2014.944497
20. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials. JAMA. 2013;310(13):1353–68. DOI: https://doi.org/10.1001/jama.2013.278040
21. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573–87. DOI: https://doi.org/10.1056/NEJMoa0807684
22. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane database of systematic reviews. 2012(7). Available from https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004143.pub5/full DOI: https://doi.org/10.1002/14651858.CD004143.pub4
23. Martin KA, Barbieri RL, Synder PJ, Crowley WF. Menopausal hormone therapy: Benefits and risks. Up To Date. 2017 Apr.
24. Malik HS. Knowledge and attitude towards menopause and hormone replacement therapy (HRT) among postmenopausal women. J Pak Med Assoc. 2008;58(4):164–7.
25. Pershad A, Morris JM, Shearer K, Pace D, Khanna P. Influencing factors on women’s attitudes toward hormone therapy acceptance for menopause treatment: a systematic review. Menopause. 2023 Oct;30(10):1061. DOI: https://doi.org/10.1097/GME.0000000000002243
26. Perrone G, Capri O, Borrello M, Galoppi P. [Attitudes toward estrogen replacement therapy. Study conducted on a sample population of women attending an ambulatory care center for the treatment of menopause]. Minerva Ginecol. 1993;45(12):603–8.
27. Chaikittisilpa S, Jirapinyo M, Chaovisitsaree S, Wipatavit V, Bunyaviroch S, Kanluan B, et al. Impact of women’s health initiative study on attitude and acceptance of hormone replacement therapy in Thai women attending menopause clinics. J Med Assoc Thai. 2007;90(4):628–35.
28. Li C, Samsioe G, Lidfelt J, Nerbrand C, Agardh CD, Women’s Health in Lund Area (WHILA) Study. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women’s Health in Lund Area (WHILA) Study. Menopause. 2000;7(4):273–81. DOI: https://doi.org/10.1097/00042192-200007040-00010
29. Rozenberg S, Vandromme J, Kroll M, Pastijn A, Liebens F. Compliance to hormone replacement therapy. Int J Fertil Menopausal Stud. 1995;40 Suppl 1:23–32.
30. Parazzini F, Progetto Menopausa Italia Study Group. Trends of determinants of hormone therapy use in Italian women attending menopause clinics, 1997-2003. Menopause. 2008;15(1):164–70. DOI: https://doi.org/10.1097/gme.0b013e318057782b
31. Buick DL, Crook D, Horne R. Women’s perceptions of hormone replacement therapy: risks and benefits (1980-2002). A literature review. Climacteric. 2005;8(1):24–35. DOI: https://doi.org/10.1080/13697130500062654
32. Çilgin H. Predictors of Initiating Hormone Replacement Therapy in Postmenopausal Women: A Cross-Sectional Study. Sci World J. 2019;2019:e1814804. DOI: https://doi.org/10.1155/2019/1814804
33. Walter FM, Emery JD, Rogers M, Britten N. Women’s views of optimal risk communication and decision making in general practice consultations about the menopause and hormone replacement therapy. Patient Educ Couns. 2004;53(2):121–8. DOI: https://doi.org/10.1016/j.pec.2003.11.001
34. Communication in high risk ante-natal consultations: a direct observational study of interactions between patients and obstetricians - PMC [Internet]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450934/ [last accessed on 2025 Mar 25]
35. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline | J Clin Endocrinol Metab | Oxford Academic [Internet] Available from: https://academic.oup.com/jcem/article/100/11/3975/2836060 [last accessed on 2025 Mar 25] DOI: https://doi.org/10.1210/jc.2015-2236
36. Chapman EN, Kaatz A, Carnes M. Physicians and Implicit Bias: How Doctors May Unwittingly Perpetuate Health Care Disparities. J Gen Intern Med. 2013;28(11):1504–10. DOI: https://doi.org/10.1007/s11606-013-2441-1
37. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women’s EMPOWER Survey: Identifying Women’s Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. J Sex Med. 2017;14(3):413–24. DOI: https://doi.org/10.1016/j.jsxm.2017.01.010
38. Meeta M, Digumarti L, Agarwal N, Vaze N, Shah R, Malik S. Clinical practice guidelines on menopause:* An executive summary and recommendations: Indian Menopause Society 2019–2020. Journal of Mid-life Health. 2020;11(2):55-95. DOI: https://doi.org/10.4103/jmh.JMH_137_20
39. Sharma S, Mahajan N. Menopausal symptoms and its effect on quality of life in urban versus rural women: A cross-sectional study. Journal of mid-life health. 2015;6(1):16-20. DOI: https://doi.org/10.4103/0976-7800.153606
40. Subramaniyan D, Ramachandran K, Viswanathan S. Economic aspects of menopausal hormone therapy among Indian women: A cross-sectional study. Indian J Med Res. 2021;153(6):737–744.
41. Gupta P, Goyal M, Kaur G, Mittal A, Sharma V, et al. Study of Menopausal Symptoms, Different Modalities and Personal Decisions for Managing Them among Urban Women in the Age Group of 40-55 Years: A Cross-Sectional Study from North India. J Womens Health, Issues Care. 2020;9:6.
42. Deshmukh, P. R., Garg, B. S., Bharambe, M. S. Qualitative study of socio-cultural and local beliefs and practices of menopause and menopausal symptoms in rural central India. BMC Women's Health. 2018;18(1), 139.
43. Reddy, P. S., Deepa, S. A study on awareness and knowledge regarding menopause and hormone replacement therapy among postmenopausal women in a rural area. International Journal of Community Medicine and Public Health, 2019;6(7):2715–2719. DOI: https://doi.org/10.18203/2394-6040.ijcmph20203003
44. Khan, Z., Puddey, I. B., Bhanji, N. M. Menopausal hormone therapy: A survey of healthcare provider perspectives in India. Climacteric. 2020;23(2):177–183.
45. Patel SS, Mehta DH. Awareness and Knowledge about Menopause and Hormone Replacement Therapy (HRT) among Postmenopausal Women. J Midlife Health. 2018;9(3):145-149.